Last reviewed · How we verify
Peginterferon alfa-2a, Ribavirin, Amantadine
Peginterferon alfa-2a, Ribavirin, Amantadine is a Antiviral combination therapy Small molecule drug developed by University of Hamburg-Eppendorf. It is currently in Phase 3 development for Chronic hepatitis C virus infection (phase 3 trial).
This triple-drug combination uses peginterferon alfa-2a and ribavirin as antivirals with immunomodulatory effects, plus amantadine as an additional antiviral agent, to suppress viral replication and enhance immune response.
This triple-drug combination uses peginterferon alfa-2a and ribavirin as antivirals with immunomodulatory effects, plus amantadine as an additional antiviral agent, to suppress viral replication and enhance immune response. Used for Chronic hepatitis C virus infection (phase 3 trial).
At a glance
| Generic name | Peginterferon alfa-2a, Ribavirin, Amantadine |
|---|---|
| Sponsor | University of Hamburg-Eppendorf |
| Drug class | Antiviral combination therapy |
| Target | Interferon-alpha receptor, viral RNA polymerase, viral M2 ion channel |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Peginterferon alfa-2a is a long-acting interferon that activates innate immunity and has direct antiviral properties. Ribavirin is a nucleoside analog that inhibits viral RNA synthesis and may enhance interferon-mediated immune responses. Amantadine is an adamantane derivative that blocks viral uncoating and has immunomodulatory effects. Together, this combination targets multiple stages of viral replication and enhances antiviral immunity.
Approved indications
- Chronic hepatitis C virus infection (phase 3 trial)
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hematologic abnormalities (anemia, thrombocytopenia, leukopenia)
- Psychiatric effects (depression, anxiety)
- Thyroid dysfunction
- Headache
- Nausea
- Insomnia
Key clinical trials
- Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients (PHASE3)
- Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy (PHASE3)
- Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peginterferon alfa-2a, Ribavirin, Amantadine CI brief — competitive landscape report
- Peginterferon alfa-2a, Ribavirin, Amantadine updates RSS · CI watch RSS
- University of Hamburg-Eppendorf portfolio CI
Frequently asked questions about Peginterferon alfa-2a, Ribavirin, Amantadine
What is Peginterferon alfa-2a, Ribavirin, Amantadine?
How does Peginterferon alfa-2a, Ribavirin, Amantadine work?
What is Peginterferon alfa-2a, Ribavirin, Amantadine used for?
Who makes Peginterferon alfa-2a, Ribavirin, Amantadine?
What drug class is Peginterferon alfa-2a, Ribavirin, Amantadine in?
What development phase is Peginterferon alfa-2a, Ribavirin, Amantadine in?
What are the side effects of Peginterferon alfa-2a, Ribavirin, Amantadine?
What does Peginterferon alfa-2a, Ribavirin, Amantadine target?
Related
- Drug class: All Antiviral combination therapy drugs
- Target: All drugs targeting Interferon-alpha receptor, viral RNA polymerase, viral M2 ion channel
- Manufacturer: University of Hamburg-Eppendorf — full pipeline
- Therapeutic area: All drugs in Virology/Infectious Disease
- Indication: Drugs for Chronic hepatitis C virus infection (phase 3 trial)